REG - Venture Life Group - Appointment of Joint Broker

Venture LifeAnnouncement

20/07/2018 07:05

RNS Number : 2296V
Venture Life Group PLC
20 July 2018
 


20 July 2018
 
Venture Life Group plc
(the "VLG or the "Company")
 
Appointment of Joint Broker
 
Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as joint broker, alongside its existing nominated adviser and joint broker Northland Capital Partners Limited and Turner Pope Investments Limited. 
 
Contacts



Venture Life Group PLC


+44 (0) 1344 742870




Jerry Randall, Chief Executive Officer








Adrian Crockett, Chief Financial Officer  


















Northland Capital Partners Limited

(Nominated Adviser and Joint Broker)


+44 (0) 20 3861 6625




Matthew Johnson / Edward Hutton (Corporate Finance)








Vadim Alexandre (Corporate Broking)


















Cenkos Securities PLC (Joint Broker)


+44 (0) 20 7397 8900




Camilla Hume / Mark Connelly (Corporate Finance)








Michael F Johnson / Russell Kerr (Sales)


















Turner Pope Investments (TPI) Ltd (Joint Broker)


+44 (0) 20 3621 4120




James Pope / Ben Turner


















Walbrook PR


+ 44 (0) 20 7933 8780




Anna Dunphy


venturelife@walbrookpr.com




+44 (0) 7876 741 001







 
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCVKLFFVDFEBBZ